Patents by Inventor James T. Dalton

James T. Dalton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Solid forms of selective androgen receptor modulators
    Patent number: 8563606
    Abstract: The present invention relates to solid forms of (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.
    Type: Grant
    Filed: June 5, 2011
    Date of Patent: October 22, 2013
    Assignee: GTx, Inc.
    Inventors: James T. Dalton, David A. Dickason, Seoung-Soo Hong, Thomas G. Bird, Tai Ahn
  • Estrogen receptor ligands and methods of use thereof
    Patent number: 8546451
    Abstract: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.
    Type: Grant
    Filed: February 23, 2010
    Date of Patent: October 1, 2013
    Assignee: GTx, Inc.
    Inventors: James T. Dalton, Mitchell S. Steiner, Jeetendra Eswaraka
  • Treating androgen decline in aging male (ADAM)-associated conditions with SARMs
    Patent number: 8445534
    Abstract: This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and/or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: May 21, 2013
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Donghua Yin, Yali He
  • ALDO-KETO REDUCTASE SUBFAMILY 1C3 (AKR1C3) INHIBITORS
    Publication number: 20130116277
    Abstract: The present invention relates to a novel class of AKR1C3 inhibitors, to compositions containing them, to methods for their preparation, and to methods of use thereof. The AKR1C3 inhibitors may be useful in the treatment of, for example, prostate cancer, benign prostate hyperplasia (BPH), lung cancer, acne, seborrhea, hirsuitism, baldness, alopecia, precocious puberty, adrenal hypertrophy, polycystic ovary syndrome, breast cancer, uterine cancer, uterine fibroids, endometriosis, myeloma and leiomyoma.
    Type: Application
    Filed: September 7, 2012
    Publication date: May 9, 2013
    Inventors: James T. DALTON, Duane D. Miller, Ramesh Narayanan, Muralimohan Yepuru, Christopher C. Coss, Michael L. Mohler, Zhongzhi Wu
  • Substituted acylanilides and methods of use thereof
    Patent number: 8426465
    Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: April 23, 2013
    Assignee: University of Tennesse Research Foundation
    Inventors: James T. Dalton, Duane D. Miller
  • SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES
    Publication number: 20130034562
    Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC, wherein the patients are subjected to cancer therapy.
    Type: Application
    Filed: July 25, 2012
    Publication date: February 7, 2013
    Inventors: James T. Dalton, Duane D. Miller
  • Therapeutic agents for the treatment of lymphoid malignancies
    Patent number: 8318812
    Abstract: Methods—for treatment and prevention of lymphoid malignancies, including, but not limited to acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute Myeloid leukemia (AML), and mantle cell lymphoma (MCL). The methods include administration of a therapeutically effective amount of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane 1,3-diol hydrochloride) or a derivative, pharmaceutically acceptable salt thereof, or a prodrug thereof to a subject.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: November 27, 2012
    Assignee: The Ohio State University Research Foundation
    Inventors: John C. Byrd, Danilo Perrotti, Ching-Shih Chen, James T. Dalton, Frank Frissora, Xiaobin Zhao, Qing Liu, Natarajan Muthusamy
  • SARMs and method of use thereof
    Patent number: 8309603
    Abstract: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: November 13, 2012
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Jeff Kearbey
  • NUCLEAR RECEPTOR BINDING AGENTS
    Publication number: 20120157539
    Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
    Type: Application
    Filed: January 31, 2012
    Publication date: June 21, 2012
    Inventors: James T. DALTON, Christina BARRETT, Duane D. MILLER, Seoung-Soo HONG, Yali HE, Michael L. MOHLER, Ramesh NARAYANAN, Zhongzhi WU
  • SUBSTITUTED ACYLANILIDES AND METHODS OF USE THEREOF
    Publication number: 20120136052
    Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.
    Type: Application
    Filed: November 22, 2011
    Publication date: May 31, 2012
    Inventors: James T. DALTON, Duane D. Miller
  • Nuclear receptor binding agents
    Patent number: 8158828
    Abstract: The present invention relates to a novel class of selective estrogen receptor modulators (SERMs). The SERM compounds are applicable for use in the prevention and/or treatment of a variety of diseases and conditions including prevention and treatment of cancers such as prostate and breast cancer, osteoporosis, hormone-related diseases, hot flashes or vasomotor symptoms, neurological disorders, cardiovascular disease and obesity.
    Type: Grant
    Filed: April 16, 2007
    Date of Patent: April 17, 2012
    Assignee: GTx, Inc.
    Inventors: James T. Dalton, Christina Barrett, Yali He, Seoung-Soo Hong, Duane D. Miller, Michael L. Mohler, Ramesh Narayanan, Zhongzhi Wu
  • ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF
    Publication number: 20120077845
    Abstract: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, and castration-resistant prostate cancer (CRPC) and palliative treatment of prostate cancer, advanced prostate cancer and castration-resistant prostate cancer (CRPC). The compounds of this invention suppress free or total testosterone levels to castrate levels which may be used to treat prostate cancer, advanced prostate cancer, and CRPC without causing bone loss, decreased bone mineral density, increased risk of bone fractures, increased body fat, hot flashes and/or gynecomastia.
    Type: Application
    Filed: August 23, 2011
    Publication date: March 29, 2012
    Inventors: James T. DALTON, Mitchell S. STEINER, Ronald A. MORTON
  • COMPOUNDS FOR TREATMENT OF CANCER
    Publication number: 20120071524
    Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
    Type: Application
    Filed: August 24, 2011
    Publication date: March 22, 2012
    Inventors: Yan Lu, Chien-Ming Li, Zhao Wang, Jianjun Chen, Wei Li, James T. DALTON, Duane D. Miller, Charles Duke, Sunjoo Ahn
  • Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
    Patent number: 8110562
    Abstract: This invention provides nuclear hormone receptor binding compounds, compositions comprising the same and methods of uses thereof in treating a variety of diseases or conditions in a subject, including, inter-alia, prostate cancer and/or diseases or disorders of bone and muscle.
    Type: Grant
    Filed: July 19, 2007
    Date of Patent: February 7, 2012
    Assignees: University of Tennessee Research Foundation, The Ohio State University Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Igor Rakov, Casey Bohl, Michael L. Mohler
  • INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR
    Publication number: 20120022121
    Abstract: Indole derivatives and analogous compounds and pharmaceutical compositions comprising the same are provided. Also provided are methods of using these compounds to inhibit tubulin polymerization in a cell associated with a proliferative disease or to treat cancer, metastatic cancer, resistant cancer or multidrug resistant cancer, including inter-alia: prostate cancer, breast cancer, melanoma, colon cancer and bladder cancer.
    Type: Application
    Filed: July 25, 2011
    Publication date: January 26, 2012
    Inventors: James T. DALTON, Duane D. MILLER, Sunjoo AHN, Charles DUKE, Dong Jin HWANG, Jun YANG
  • Treating benign prostate hyperplasia with SARMS
    Patent number: 8088828
    Abstract: This invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of benign prostate hyperplasia in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of treating a subject suffering from hair loss, comprising the step of administering to the subject a therapeutically effective amount of a 5-? reductase enzyme type 1 and/or type 2 inhibitor, wherein said inhibitor is a selective androgen receptor modulator (SARM) and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein.
    Type: Grant
    Filed: June 30, 2010
    Date of Patent: January 3, 2012
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller, Mitchell S. Steiner, Karen A. Veverka, Wenqing Gao
  • Substituted acylanilides and methods of use thereof
    Patent number: 8080682
    Abstract: This invention provides SARM compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, a muscle wasting disease and/or disorder or a bone-related disease and/or disorder.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: December 20, 2011
    Assignee: University of Tennessee Research Foundation
    Inventors: James T. Dalton, Duane D. Miller
  • SOLID FORMS OF SELECTIVE ANDROGEN RECEPTOR MODULATORS
    Publication number: 20110263703
    Abstract: The present invention relates to solid forms of (S)-N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide and process for producing the same.
    Type: Application
    Filed: June 5, 2011
    Publication date: October 27, 2011
    Inventors: James T. Dalton, David A. Dickason, Seoung-Soo Hong, Thomas G. Bird, Tai Ahn
  • COMPOUNDS FOR TREATMENT OF CANCER
    Publication number: 20110257196
    Abstract: The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
    Type: Application
    Filed: December 29, 2010
    Publication date: October 20, 2011
    Inventors: Yan Lu, Chien-Ming Li, Zhao Wang, Jianjun Chen, Wei Li, James T. Dalton, Duane D. Miller, Charles Duke, Sunjoo Ahn
  • SELECTIVE ANDROGEN RECEPTOR MODULATORS FOR TREATING DIABETES
    Publication number: 20110237664
    Abstract: This invention provides use of a SARM compound or a composition comprising the same in treating and preventing muscle wasting in patients with non-small cell lung cancer (NSCLC); treating pre-cachexia or early cachexia (preventing muscle wasting in a cancer patient); treating and preventing loss of physical function due to cancer or cancer therapy; increase of physical function; and increasing survival in a patient with NSCLC.
    Type: Application
    Filed: April 8, 2011
    Publication date: September 29, 2011
    Inventors: James T. Dalton, Shontelle Dodson, Mitchell S. Steiner